New ADCs Join NCCN Guidelines for Gynecologic Cancers Representing Step Forward
Stephanie Gaillard, MD, PhD, details cervical and ovarian cancer NCCN guideline updates, as well as unmet needs associated with molecular markers.
Stephanie Gaillard, MD, PhD, details cervical and ovarian cancer NCCN guideline updates, as well as unmet needs associated with molecular markers.
Brexu-cel led to an ORR of 91% in patients with relapsed/refractory MCL who were naive to BTK inhibitors, according to new data from the ZUMA-2…
If approved, durvalumab will be the first and only perioperative immunotherapy regimen available for the treatment of patients with muscle-invasive bladder cancer in this curative-intent…
An abstract is unavailable.
BGB-16673 monotherapy showed early activity and a tolerable safety profile in relapsed/refractory Waldenström macroglobulinemia, CLL, and SLL.
An abstract is unavailable.
Hematologic oncology specialists review recent data from the PERSEUS trial analyzing minimal residual disease in patients with newly diagnosed multiple myeloma who receive DARA-VRd.
Take this survey powered by surveymonkey.com. Create your own surveys for free.
Edited by Associate Editor Michael Hallek and Podcast Editor Laurie H. Sehn, this Review Series highlights the biologic features of, clinical phenotype of,
After an additional 7 months of follow-up, IMNN-001 plus chemotherapy produced a 13-month increase in median OS in advanced ovarian cancer
In this issue of Blood, Chakraborty et al show that the presence of 1q gain in amyloid light chain (AL) amyloidosis is associated with a lower…